logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10912843 B1

PDFFull Text
Date of Patent:
Feb. 09, 2021

Filed:

Jan. 31, 2019

Endoplasmic reticulum-targeting nanovehicles and methods for use thereof

Applicant:

National Cheng Kung University, Tainan, TW;

Inventors:

Chi-Chang Shieh, Tainan, TW;

Chia-Liang Yen, Tainan, TW;

Dar-Bin Shieh, Tainan, TW;

Si-Tse Jiang, Tainan, TW;

Assignee:

National Cheng Kung University, Tainan, TW;

Attorney:

Cesari & McKenna, LLP

Primary Examiner:

Lianko G Garyu

Int. Cl.
CPC ...
A61K 47/69 (2017.01); A61K 36/9066 (2006.01); A61K 47/59 (2017.01); A61P 37/00 (2006.01); A01K 67/027 (2006.01); A61K 9/00 (2006.01); A61K 36/06 (2006.01); A61K 36/22 (2006.01); A61K 36/23 (2006.01); A61K 36/9062 (2006.01); A61K 31/05 (2006.01); A61K 31/365 (2006.01); A61K 31/55 (2006.01); A61K 31/407 (2006.01); A61K 45/06 (2006.01); A61K 31/12 (2006.01); A61K 31/58 (2006.01); A61P 43/00 (2006.01); A61K 31/7048 (2006.01);
U.S. Cl.
CPC ...
A61K 47/6925 (2017.08); A01K 67/0275 (2013.01); A01K 67/0278 (2013.01); A61K 9/0056 (2013.01); A61K 31/05 (2013.01); A61K 31/12 (2013.01); A61K 31/365 (2013.01); A61K 31/407 (2013.01); A61K 31/55 (2013.01); A61K 31/58 (2013.01); A61K 31/7048 (2013.01); A61K 36/06 (2013.01); A61K 36/22 (2013.01); A61K 36/23 (2013.01); A61K 36/9062 (2013.01); A61K 36/9066 (2013.01); A61K 45/06 (2013.01); A61K 47/593 (2017.08); A61P 37/00 (2018.01); A61P 43/00 (2018.01); A01K 2217/075 (2013.01); A01K 2217/206 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0306 (2013.01);
Abstract

A method for treating a disease caused by protein retention in the endoplasmic reticulum (ER) with a sarcoplasmic/endoplasmic reticulum calcium ATPase pump inhibitor encapsulated in a polymer nanoparticle. The polymer nanoparticle is surface-modified such that it is targeted to the ER. The inhibitor reduces protein retention in the ER and the encapsulation lowers side effects of the inhibitor, e.g., cytotoxicity, as compared to administering the inhibitor without encapsulation. Also disclosed is a pharmaceutical composition that can be used for carrying out the method. Further provided is a transgenic mouse carrying in its genome a heterologous nucleic acid that encodes an H338Y mutant gp91protein. The transgenic mouse can serve as a model for human chronic granulomatous disease.

Find Patent Forward Citations

Loading…